Document Detail

Should evaluation for minimal residual disease be routine in acute myeloid leukemia?
MedLine Citation:
PMID:  23380603     Owner:  NLM     Status:  In-Data-Review    
PURPOSE OF REVIEW: In patients with acute myeloid leukemia (AML), measuring response to treatment is essential to guide clinical decisions. Methods for detecting disease beyond the resolution limit of morphology (i.e., minimal residual disease, MRD) are now widely available. We here discuss their merits and the results of side-to-side comparisons.
RECENT FINDINGS: The ever-increasing comprehension of the molecular genetics of AML has led to the identification of targets for molecular monitoring of MRD in the majority of AML cases. Likewise, virtually all cases express aberrant immunophenotypes suitable for MRD monitoring by flow cytometry, a progress bolstered by powerful new-generation instruments. The clinical significance of MRD monitoring by either approach has been corroborated by recent results. However, with few exceptions, most of the studies continue to rely on retrospectively determined cut-off levels and time points. Moreover, when applied in parallel, the two approaches have yielded contradictory results.
SUMMARY: MRD monitoring can help predicting the risk of relapse better than morphology and also provide endpoints for clinical testing of experimental agents. MRD can be applied to guide therapy but one must carefully consider the characteristics of the methods used and the degree of expertise of the laboratory performing the test.
Elaine Coustan-Smith; Dario Campana
Related Documents :
23320753 - Label free quantification for discovering novel biomarkers in diagnosing and assessing ...
21222623 - Prolyl oligopeptidase: a rising star on the stage of neuroinflammation research.
11006403 - A biomechanical model of peyronie's disease.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current opinion in hematology     Volume:  20     ISSN:  1531-7048     ISO Abbreviation:  Curr. Opin. Hematol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-02-05     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9430802     Medline TA:  Curr Opin Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  86-92     Citation Subset:  IM    
Department of Paediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The evolving molecular genetic landscape in acute myeloid leukaemia.
Next Document:  Pupil centroid shift and cyclotorsion in bilateral wavefront-guided laser refractive surgery and the...